Nurix Therapeutics CSO Gwenn Hansen sells $36,300 in common stock
Nurix Therapeutics' Chief Scientific Officer, Gwenn Hansen, sold 1,452 shares of the company's common stock on October 15, 2026, for a total of $36,300. This sale was executed in accordance with a pre-approved Rule 10b5-1 trading plan. The shares were sold at a rate of $25.00 per share, following the exercise of employee stock options. Post-sale, Hansen currently owns 117,227 shares of Nurix Therapeutics common stock.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- United Therapeutics CEO Rothblatt sells $5.1m in shares investing.com
